Dyne Therapeutics Inc 2024年度报告

Dyne Therapeutics, Inc. Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES☒NO☐ Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.YES☒NO☐Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submitsuch files).YES☒NO☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. Large accelerated filer☒Non-accelerated filer☐ Accelerated filer☐Smaller reporting company☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm thatprepared or issued its audit report.☒If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.☐Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES☐NO☒The aggregate market value of Common Stock held by non-affiliates of the registrant computed by reference to the price of the registrant’s CommonStock as of June 28, 2024, the last business day of the registrant’s most recently completed second fiscal quarter, was approximately$3.0billion(based on the last reported sale price on the Nasdaq Global Select Market as of such date). For this computation, the registrant has excluded themarket value of all shares of Common Stock reported as beneficially owned by its executive officer and directors; such exclusion shall not be deemedto constitute an admission that any such person is an affiliate of the registrant.The number of shares of Registrant’s Common Stock outstanding as of February 21, 2025 was113,121,357. DOCUMENTS INCORPORATED BY REFERENCEThe Registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2025 Annual Meeting of Stockholders within 120 days of the end of the Registrant’s fiscal year endedDecember 31, 2024. Portions of such definitive proxy statement are incorporated by referenceinto Part III of this Annual Report on Form 10-K to the extent stated herein. Table of Contents PART I Item 1.BusinessItem 1A.Risk FactorsItem 1B.Unresolved Staff CommentsItem 1C.CybersecurityItem 2.PropertiesItem 3.Legal ProceedingsItem 4.Mine Safety Disclosures PART IIItem 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases ofEquity Securities123Item 6.[Reserved]124Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations125Item 7A.Quantitative and Qualitative Disclosures About Market Risk137Item 8.Financial Statements and Supplementary Data137Item 9.Changes in and Disagreements With Accountants on Accounting and Financial Disclosure137Item 9A.Controls and Procedures137Item 9B.Other Information140Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspection140 PART IIIItem 10. Directors, Executive Officers and Corporate Governance141Item 11.Executive Compensation141Item 12.Security Ownership of Certain Beneficial Owners and Management and Related StockholderMatters141Item 13.Certain Relationships and Related Transactions, and Director Independence141Item 14.Principal Accounting Fees and Services141 PART IVItem 15. Exhibits and Financial Statement Schedules142Item 16Form 10-K Summary145 Cautionary Note Regarding Forward-Looki